Circio Holding ASA (FRA:TA50)
Germany · Delayed Price · Currency is EUR | Market Cap | 285.66M +5,147.3% |
| Revenue (ttm) | n/a |
| Net Income | -3.88M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.086 |
| Previous Close | 0.996 |
| Day's Range | 1.086 - 1.086 |
| 52-Week Range | 0.041 - 1.330 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAss... [Read more]
News
Circio Holding ASA Slides: Investor update
Circio Holding ASA has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Circio Holding ASA Slides: Corporate presentation
Circio Holding ASA has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Circio Holding ASA Annual report: Q4 2025
Circio Holding ASA has published its Q4 2025 annual report on April 15, 2026.
Circio Holding ASA Transcript: R&D update
circVec technology shows robust, reproducible, and highly potent gene expression in heart and eye, with significant dose-sparing and safety advantages. The platform is advancing disease-specific constructs and in vivo CAR applications, supported by strong fundraising and ongoing collaborations.
Circio Holding ASA Press release: R&D update
Circio Holding ASA issued a press release on February 26, 2026, disclosing material business information to investors.
Circio Holding ASA Slides: R&D update
Circio Holding ASA has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Circio Holding ASA Slides: Status update
Circio Holding ASA has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.
Circio Holding ASA Transcript: R&D Update
circVec technology delivers significantly higher and more durable protein expression than conventional approaches, with strong preclinical results in heart, eye, and CNS models. Lead programs are advancing toward key efficacy milestones, supported by new pharma collaborations and a robust financial position.
Circio Holding ASA Press release: R&D Update
Circio Holding ASA issued a press release on November 24, 2025, disclosing material business information to investors.
Circio Holding ASA Slides: R&D Update
Circio Holding ASA has posted slides in relation to its latest quarterly earnings report, which was published on November 24, 2025.
Circio Holding ASA Earnings Call Transcript: Q2 2025
Strong R&D progress with circVec platform led to up to 44x improved heart expression and 15x in eye, while financial stability was secured through extended Atlas financing. Seven new collaborations and a lean cost structure position the company for further growth and new partnerships.
Circio Holding ASA Quarterly report: Q2 2025
Circio Holding ASA has published its Q2 2025 quarterly earnings report on August 28, 2025.
Circio Holding ASA Slides: Q2 2025
Circio Holding ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 28, 2025.